What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review Read More > February 11, 2021
Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical Research Read More > February 3, 2021
Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression Read More > January 22, 2021
Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depression Read More > January 22, 2021
Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants Read More > January 20, 2021
Classical Psychedelics as Therapeutics in Psychiatry – Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders Read More > January 20, 2021
A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT 2A Receptor Density in the Pig Brain Read More > January 15, 2021
Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants Read More > January 11, 2021
Ketamine treatment for depression: qualitative study exploring patient views Read More > January 11, 2021
Adverse Effects of Esketamine for the Treatment of Major Depression Disorder: Findings from Randomized Controlled Trials Read More > January 7, 2021
